IIFL Fintech Fund Exits Finarkein Analytics With Over 2X Return in 3 Years
IIFL Fintech Fund, an early-stage fund focused on the fintech sector, has announced a successful exit from its investment in Finarkein Analytics, a financial data analytics firm.
The exit, achieved at more than double the valuation in just three years, marks the fund's second profitable exit, following the sale of fraud detection firm TrustCheckr to global caller identification platform Truecaller in October 2023. The fund earned ~80% returns on the TrustCheckr investment in only 18 months.
Finarkein Analytics enables enterprises to build data products leveraging India's emerging digital public infrastructure (DPI) such as the Account Aggregator ecosystem, ONDC-Financial Services, and OCEN.
"With Finarkein also, we went beyond the business aspect to enhance their overall product and platform to ensure faster business adoption," said Mehekka Oberoi, Fund Manager at IIFL Fintech Fund. "Attaining a more than 100% return and ensuring liquidity to our investors underscores our commitment. We had earlier successfully exited TrustCheckr within 18 months. The fund is committed to giving cashflows to investors from time to time."
Launched in 2021, IIFL Fintech Fund has invested in 14 fintech startups including Leegality, FinBox, DataSutram, Finvu, Trendlyne, and Vitra.AI. The fund boasts a 26.2X revenue growth across its portfolio over three years, with 40% of the startups being EBIDTA positive and no write-offs or deadpool cases.
Recently, IIFL Fintech Fund also announced the first close of its Series II fund, securing over INR 200 crore. The new fund aims to back the next wave of fintech innovation in India, including ventures in generative AI.
The Indian fintech ecosystem continues to present vast opportunities. "There is a 3-5X gap between India and developed markets in areas like insurance, lending, and mutual fund assets," the fund said in a statement. "This makes fintech one of the most promising sectors in India's growth story."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
How (and Why) To Stay in the Market Even at All-Time Highs
One of the most famous mantras in the investment world is to 'buy low and sell high.' With the S&P 500 setting record after record in 2025 — and valuations reaching stratospheric levels — it might seem like buying now is the exact wrong thing to do. Read More: Find Out: But there are still compelling reasons to stay in the market, even at all-time highs. Here's why — and how you can do it. The Market Consistently Makes New 'All-Time' Highs Markets don't go up in a straight line, but history shows the S&P 500 has always gone on to make new highs, no matter how severe a bear market it endures. The fact that the index is at an all-time high as of July 2025 means that by definition, all of its past bad days and bad years are now in the rear-view mirror. Investors who have held on — or even added to their positions — during prior downturns have been handsomely rewarded with the highest price in the index's history. Discover More: Market Technicians Love New Highs Technical research interprets past trading patterns to predict future market movements. Many technicians view a new market high as a 'breakout,' indicating future upside to come. Numerous other factors can help support this prediction, such as rising trading volume and increasing market breadth, but in its most simplistic form, technical analysis usually views a fresh market high as an indication that prices will continue to go higher. Timing the Market Leads To Underperformance If you could always buy at the stock market's low and sell at its high, yes, you'd have a great trading record that would significantly outperform the overall market. But history, along with the shattered portfolios of numerous traders before you, shows that doing that consistently is all but impossible. A more likely scenario is that you emotionally panic and sell your positions when the market is crashing and then start investing again after the market has made significant gains — right before the next bear market. Another common scenario is that you fear the S&P 500 is 'overvalued' and you sell all your positions as the market goes higher and higher. Missing out on even a few of the best days in the market is enough to keep your portfolio in a perpetual state of underperformance, but it's a relatively common occurrence among those trying to time the market. What Can You Do? Investing at market highs is something of a double-edged sword. On the one hand, it's a great time to be invested in the S&P 500, because it means your portfolio should also be at all-time highs. However, it can also be a bit nerve-wracking because valuations are stretched to their limit, and the market is 'priced for perfection' — meaning everything has to continue doing well to support those lofty prices. As fear of losing money is generally greater for investors than the joy from profiting, it's natural to feel a bit queasy when market prices are high. For most long-term investors, the best strategy is to stay the course. By investing consistently, regardless of the S&P 500's current condition, you end up with an average price that smooths out the market's ups and downs. If the market continues to go higher, you'll keep profiting from your investments, even the ones you made at a 'high' price. If the market falls, your ongoing investments will pick up shares at lower prices, leading to even greater profits in the future. Many advisors recommend that investors increase their contributions while markets are falling so they can benefit even more from 'on-sale' share prices. While perhaps not a perfect system, consistent investing is a much better option than trying to time the market based on emotion and instinct. That has proven time and time again to be a losing game in the long run. More From GOBankingRates New Law Could Make Electricity Bills Skyrocket in These 4 States I'm a Self-Made Millionaire: 6 Ways I Use ChatGPT To Make a Lot of Money 5 Strategies High-Net-Worth Families Use To Build Generational Wealth Mark Cuban Says Trump's Executive Order To Lower Medication Costs Has a 'Real Shot' -- Here's Why This article originally appeared on How (and Why) To Stay in the Market Even at All-Time Highs
Yahoo
an hour ago
- Yahoo
MediaCo Holding (NASDAQ:MDIA) shareholders have endured a 71% loss from investing in the stock five years ago
Explore MediaCo Holding's Fair Values from the Community and select yours While it may not be enough for some shareholders, we think it is good to see the MediaCo Holding Inc. (NASDAQ:MDIA) share price up 28% in a single quarter. But will that heal all the wounds inflicted over 5 years of declines? Unlikely. In fact, the share price has tumbled down a mountain to land 71% lower after that period. It's true that the recent bounce could signal the company is turning over a new leaf, but we are not so sure. The fundamental business performance will ultimately determine if the turnaround can be sustained. Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. During five years of share price growth, MediaCo Holding moved from a loss to profitability. That would generally be considered a positive, so we are surprised to see the share price is down. Other metrics may better explain the share price move. In contrast to the share price, revenue has actually increased by 20% a year in the five year period. So it seems one might have to take closer look at the fundamentals to understand why the share price languishes. After all, there may be an opportunity. The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers). If you are thinking of buying or selling MediaCo Holding stock, you should check out this FREE detailed report on its balance sheet. A Different Perspective While the broader market gained around 19% in the last year, MediaCo Holding shareholders lost 70%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 11% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 4 warning signs with MediaCo Holding (at least 2 which can't be ignored) , and understanding them should be part of your investment process. If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
an hour ago
- Yahoo
We're Hopeful That BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Will Use Its Cash Wisely
Explore BridgeBio Oncology Therapeutics's Fair Values from the Community and select yours Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly. So should BridgeBio Oncology Therapeutics (NASDAQ:BBOT) shareholders be worried about its cash burn? For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. How Long Is BridgeBio Oncology Therapeutics' Cash Runway? You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. As at December 2024, BridgeBio Oncology Therapeutics had cash of US$156m and no debt. In the last year, its cash burn was US$55m. That means it had a cash runway of about 2.8 years as of December 2024. That's decent, giving the company a couple years to develop its business. Depicted below, you can see how its cash holdings have changed over time. View our latest analysis for BridgeBio Oncology Therapeutics How Is BridgeBio Oncology Therapeutics' Cash Burn Changing Over Time? Because BridgeBio Oncology Therapeutics isn't currently generating revenue, we consider it an early-stage business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. With the cash burn rate up 4.9% in the last year, it seems that the company is ratcheting up investment in the business over time. That's not necessarily a bad thing, but investors should be mindful of the fact that will shorten the cash runway. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company. How Hard Would It Be For BridgeBio Oncology Therapeutics To Raise More Cash For Growth? Since its cash burn is increasing (albeit only slightly), BridgeBio Oncology Therapeutics shareholders should still be mindful of the possibility it will require more cash in the future. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Many companies end up issuing new shares to fund future growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations. BridgeBio Oncology Therapeutics has a market capitalisation of US$921m and burnt through US$55m last year, which is 6.0% of the company's market value. That's a low proportion, so we figure the company would be able to raise more cash to fund growth, with a little dilution, or even to simply borrow some money. Is BridgeBio Oncology Therapeutics' Cash Burn A Worry? As you can probably tell by now, we're not too worried about BridgeBio Oncology Therapeutics' cash burn. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. Although its increasing cash burn does give us reason for pause, the other metrics we discussed in this article form a positive picture overall. Looking at all the measures in this article, together, we're not worried about its rate of cash burn; the company seems well on top of its medium-term spending needs. On another note, BridgeBio Oncology Therapeutics has 5 warning signs (and 3 which are concerning) we think you should know about. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies with significant insider holdings, and this list of stocks growth stocks (according to analyst forecasts) Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
